dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
Pre-clinicalUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ST-segment Elevation Myocardial Infarction
Conditions
ST-segment Elevation Myocardial Infarction
Trial Timeline
Jan 11, 2017 → Mar 1, 2023
NCT ID
NCT03062826About dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel)
dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) is a pre-clinical stage product being developed by Shenzhen Salubris Pharmaceuticals for ST-segment Elevation Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT03062826. Target conditions include ST-segment Elevation Myocardial Infarction.
What happened to similar drugs?
0 of 1 similar drugs in ST-segment Elevation Myocardial Infarction were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03062826 | Pre-clinical | UNKNOWN |
Competing Products
1 competing product in ST-segment Elevation Myocardial Infarction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Butylphthalide + Butylphthalide placebo | CSPC Pharmaceutical Group Limited | Phase 3 | 47 |